Telomere shortening protects against cancer

December 01, 2020

As time goes by, the tips of your chromosomes--called telomeres--become shorter. This process has long been viewed as an unwanted side-effect of aging, but a recent study shows it is in fact good for you.

"Telomeres protect the genetic material," says Titia de Lange, Leon Hess Professor at Rockefeller. "The DNA in telomeres shortens when cells divide, eventually halting cell division when the telomere reserve is depleted."

New results from de Lange's lab provide the first evidence that telomere shortening helps prevent cancer in humans, likely because of its power to curtail cell division. Published in eLife, the findings were obtained by analyzing mutations in families with exceptional cancer histories, and they present the answer to a decades-old question about the relationship between telomeres and cancer.

A longstanding controversy

In stem cells, including those that generate eggs and sperm, telomeres are maintained by telomerase, an enzyme that adds telomeric DNA to the ends of chromosomes. Telomerase is not present in normal human cells, however, which is why their telomeres wither away. This telomere shortening program limits the number of divisions of normal human cells to about 50.

The idea that telomere shortening could be part of the body's defense against cancer was first proposed decades ago. Once an early-stage tumor cell has divided 50 times, scientists imagined, depletion of the telomere reserve would block further cancer development. Only those cancers that manage to activate telomerase would break through this barrier.

Clinical observations seemed to support this hypothesis. "Most clinically detectable cancers have re-activated telomerase, often through mutations," de Lange says. Moreover, mouse experiments showed that shortening telomeres can indeed protect against cancer. Nonetheless, evidence for the telomere tumor suppressor system remained elusive for the past two decades, and its existence in humans remained controversial.

The solution to a decades-old problem

The telomere tumor suppressor pathway can only work if we are born with telomeres of the right length; if the telomeres are too long, the telomere reserve would not run out in time to stop cancer development. Longer telomeres will afford cancer cells additional divisions during which mutations can creep into the genetic code, including mutations that activate telomerase.

For decades, de Lange's lab has been studying the complex process by which telomeres are regulated. She and others identified a set of proteins that can limit telomere length in cultured human cells, among them a protein called TIN2. When TIN2 is inhibited, telomerase runs wild and over-elongates telomeres. But it was not known whether TIN2 also regulated telomere length at birth.

The stalemate on the telomere tumor suppressor continued until physicians at the Radboud University Medical Center in Holland reached out to de Lange about several cancer-prone families.  The doctors found that these families had mutations in TINF2, the gene that encodes the TIN2 protein instrumental to controlling telomere length. That's when they asked de Lange to step in.

Isabelle Schmutz, a Women&Science postdoctoral fellow in the de Lange lab, used CRISPR gene-editing technology to engineer cells with precisely the same mutations as those seen in the Dutch families and examined the resulting mutant cells. She found that the mutant cells had fully functional telomeres and no genomic instability. They were, for all intents and purposes, normal healthy cells.

But there was one thing wrong with the cells. "Their telomeres became too long, " de Lange says.  Similarly, the patient's telomeres were unusually long. "These patients have telomeres that are far above the 99th percentile," de Lange says.

"The data show that if you're born with long telomeres, you are at greater risk of getting cancer, " says de Lange. "We are seeing how the loss of the telomere tumor suppressor pathway in these families leads to breast cancer, colorectal cancer, melanoma, and thyroid cancers. These cancers would normally have been blocked by telomere shortening. The broad spectrum of cancers in these families shows the power of the telomere tumor suppressor pathway."

The study is demonstration of the power of basic science to transform our understanding of medicine. "How telomeres are regulated is a fundamental problem," de Lange says. "And by working on a fundamental problem, we were eventually able to understand the origins of a human disease."
-end-


Rockefeller University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.